
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **COL1A2, COL1A1, COL3A1, COL5A2, COL6A3, COL6A1, COL6A2, COL10A1, COL11A1, COL12A1, COL5A1**: These are collagen genes, which are structural proteins that play a critical role in the extracellular matrix (ECM) and are often associated with connective tissue.<br>- **LUM (Lumican), DCN (Decorin), BGN (Biglycan)**: These are small leucine-rich proteoglycans involved in collagen fibrillogenesis and ECM organization.<br>- **SPARC (Secreted Protein Acidic and Rich in Cysteine), POSTN (Periostin), FN1 (Fibronectin), VCAN (Versican), THBS2 (Thrombospondin 2), FBN1 (Fibrillin 1)**: These are ECM proteins involved in cell adhesion, migration, and tissue repair.<br>- **MMP2, MMP11**: Matrix metalloproteinases involved in the breakdown of ECM components, important for tissue remodeling.<br>- **FAP (Fibroblast Activation Protein), CTGF (Connective Tissue Growth Factor), SFRP2, SFRP4**: Involved in tissue remodeling and fibrosis.<br>- **THY1 (CD90), CDH11 (Cadherin 11), CXCL12 (C-X-C Motif Chemokine Ligand 12)**: Involved in cell-cell adhesion and signaling.<br>- **CTSK (Cathepsin K), AEBP1 (Adipocyte Enhancer-Binding Protein 1), RARRES2 (Retinoic Acid Receptor Responder 2), CTHRC1 (Collagen Triple Helix Repeat Containing 1)**: Involved in ECM remodeling and cell differentiation.<br><br>### Step 2: List the Key Cell Type Markers<br>- **COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, COL6A1, COL6A2, COL6A3, COL11A1, COL12A1**: These collagens are highly expressed in fibroblasts, which are the primary cells responsible for producing and maintaining the ECM.<br>- **LUM, DCN, BGN**: These proteoglycans are also characteristic of fibroblasts.<br>- **FAP, THY1, CDH11**: These markers are commonly associated with activated fibroblasts or cancer-associated fibroblasts (CAFs).<br><br>### Step 3: Cross-reference Known Databases<br>Using scRNA-seq databases such as the Human Cell Atlas and literature on breast cancer stroma, the expression of these markers is consistent with fibroblasts, particularly cancer-associated fibroblasts (CAFs), which are known to play a role in tumor progression and ECM remodeling.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of collagen genes, ECM proteins, and fibroblast-specific markers, the most probable general cell type is **fibroblasts**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Cancer-Associated Fibroblasts (CAFs)**: Given the context of breast cancer tissue and the presence of markers like FAP, THY1, and MMPs, CAFs are the most likely subtype.<br>2. **Myofibroblasts**: Characterized by the expression of ECM components and contractile proteins like TAGLN (Transgelin), which is also present in the list.<br>3. **Adventitial Fibroblasts**: These are fibroblasts associated with blood vessels, and markers like VCAN and FN1 suggest a role in vascular ECM.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The ranked marker list from the breast cancer tissue dataset is indicative of fibroblasts, with a strong emphasis on ECM production and remodeling. The presence of specific markers such as FAP, THY1, and MMPs suggests that these are cancer-associated fibroblasts (CAFs), which are known to contribute to the tumor microenvironment by remodeling the ECM and facilitating tumor progression. Myofibroblasts and adventitial fibroblasts are also possible subtypes, but CAFs are the most likely given the context and marker expression.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the context of breast cancer tissue. Here's the breakdown of the validation:<br><br>1. **Marker Consistency**: <br>   - The markers listed in the annotation result are present in the provided marker list. <br>   - The identified cell type, fibroblasts, particularly cancer-associated fibroblasts (CAFs), is consistent with the expression of collagen genes, ECM proteins, and fibroblast-specific markers such as FAP, THY1, and MMPs.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation considers the possibility of mixed cell types by identifying potential subtypes such as myofibroblasts and adventitial fibroblasts. However, the strong presence of CAF-specific markers supports the primary annotation of CAFs.<br>   - There is no strong evidence of multiple distinct cell types that would necessitate further investigation for mixed populations.<br><br>Overall, the annotation is well-supported by the marker list and the context of the dataset, leading to a valid conclusion of fibroblasts, with a focus on cancer-associated fibroblasts.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">fibroblasts</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Cancer-Associated Fibroblasts (CAFs)</li><li>Myofibroblasts</li><li>Adventitial Fibroblasts</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided for the single-cell dataset derived from human breast cancer tissue are generally well-executed, with a strong focus on identifying fibroblasts, particularly cancer-associated fibroblasts (CAFs). The analysis effectively utilizes the ranked marker list to determine the most probable cell types, demonstrating a good understanding of the biological context.<br><br>1. **Correctness of Annotations**: The identification of fibroblasts, especially CAFs, is scientifically accurate given the prominence of collagen genes and ECM-related proteins in the marker list. The presence of markers such as FAP, THY1, and MMPs strongly supports the annotation of CAFs, which are known to play a significant role in the tumor microenvironment of breast cancer.<br><br>2. **Balanced Consideration of Multiple Markers**: The annotation process shows a balanced consideration of multiple markers, rather than over-focusing on a specific one. The analysis includes a wide range of ECM components, proteoglycans, and fibroblast-specific markers, which collectively support the identification of fibroblasts and their subtypes.<br><br>3. **Comprehensive View of Cell Types**: The annotation provides a comprehensive view by considering potential subtypes such as myofibroblasts and adventitial fibroblasts. This consideration of subtypes adds depth to the analysis and acknowledges the complexity of the tumor microenvironment.<br><br>4. **Consideration of Marker Rank**: The analysis appropriately considers the rank of the markers, with key fibroblast markers like COL1A1, COL1A2, and COL3A1 appearing early in the list, reinforcing their importance in the annotation.<br><br>5. **Potential Oversights**: While the annotation is robust, it could have further explored the possibility of mixed cell populations or other cell types that might be present in the tumor stroma, even if they are less prominent. However, given the strong presence of fibroblast markers, this is a minor oversight.<br><br>Overall, the annotation is well-supported by the data and provides a clear and accurate depiction of the cell types present in the dataset, with a focus on fibroblasts and their role in breast cancer tissue.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    